Human T-cell Lymphotropic Virus Type I-Associated Adult T-cell Leukemia-Lymphoma: New Directions in Clinical Research |...
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro . ... Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ... Proteasome inhibitors. The proteasome inhibitor bortezomib suppresses the activation of NF-κB, which is constitutively ... This agent effectively inhibits the growth of ATL cells both in vivo and in vitro (69). A phase II study of bortezomib is now ...
Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment | Clinical Cancer Research
Inhibitors of the immunoproteasome, such as the PR-924 inhibitor of the LMP-7 immunoproteasome subunit, also block MM growth in ... Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002 ... The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma ... PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in ...
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal...
... and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-5 ... The hepatocyte growth factor/scatter factor (HGF/SF)-c-Met axis has been implicated in the growth, survival, and migration of ... Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met ... a small-molecule inhibitor of c-Met, vascular endothelial growth factor receptor 2, Kit, Ret, Flt3, and Tie-2, has been ...
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase...
... polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in womens cancers: a dose ... Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase ... Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase ... Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase ...
Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells |...
COX-2 inhibitors and, in part, COX-1 inhibitor blocked ET-1-induced PGE2 and vascular endothelial growth factor release, ... COX-2 inhibitors NS-398 (1 μm) and SC-58125 (70 nm), as well as the non-COX isotype-selective inhibitor indomethacin (26 μm), ... Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib ... ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy ...
Plus it
Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol (Baltimore, ... Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006;66:7775-82. ... AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 2014;147:473-85. ... However, this would be of value because TAM and AI inhibit breast cancer growth by different mechanisms (28). The AIs block ...
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in...
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to ... Nonclinical safety evaluation of a transforming growth factor β receptor I kinase inhibitor in Fischer 344 rats and beagle dogs ... First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in ... First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in ...
Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model |...
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib ... The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with ... Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head ... Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with ...
Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO...
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer ... However, the retinoid 9-cis-retinoic acid (4), inhibitors of the epidermal growth factor receptor such as gefitinib (5), and ... 3) and either arrested the growth of 64% of tumors in MMTV-neu mice or reduced the volume in 22% of the tumors (Table 1). We ... 268 inhibits angiogenesis in vitro and in vivo. We have reported recently that CDDO-Me blocked angiogenesis and the growth of ...
Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression,...
Dennig J, Beato M, Suske G. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. EMBO J, 15: 5659-67, ... insulin-like growth factor receptor (41) , hepatocyte growth factor receptor (42, 43, 44) , insulin-like growth factor binding ... Molecular markers of poor prognosis include fibroblast growth factor receptor 1 (36) , epidermal growth factor receptor (37, 38 ... et al The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c- ...
HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment | Clinical Cancer Research
The hepatocyte growth factor (HGF) receptor, Met, has been implicated in HNSCC tumorigenesis and EGFR inhibitor resistance. HGF ... Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of ... Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells. J Biol Chem 2008;283: ... Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling ...
Table of Contents | Clinical Cancer Research
The Akt Inhibitor ISC-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model ... SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo ... Modeling the Tumor Growth Profiles in Xenograft Experiments-Response. Lili Zhao, Meredith A. Morgan, Leslie A. Parsels, ... Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes ...
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient...
Relative tumor growth index (TGI) was calculated by relative tumor growth of treated mice (T) divided by relative tumor growth ... AZD0530, a Src kinase inhibitor, induced only modest inhibition of tumor growth in PDA xenografts and, as expected, failed in a ... Tumor growth regressions in GEM plus MK-1775 treated mice were found to be significant in PANC198 (P , 0.0001), PANC215 (P , ... Tumor growth curves of (A) PANC374, (B) PANC185, and (C) PANC215 suggest that the combination of MK-1775 and GEM lead to ...
Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2...
At this time point, the tumor growth curves were just beginning to separate (Figs. 1 and 2) and inhibitors of VEGFR (22) and ... Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway ... Increased inhibition of tumor growth in mice treated with the combination of inhibitors of EGFR and VEGF signaling were ... In addition, EGFR inhibitors can have antitumor effects in the vascular compartment of tumors (1), and VEGFR inhibitors can ...
Plus it
First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in ... Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type ... Two TGFβ inhibitors, HTS466284 (HTS) and RER, were used. HTS466284 (HTS) is an ATP competitive inhibitor of TGFβ type I ... TGFβ receptor kinase inhibitors are the most commonly used TGFβ inhibitor for preclinical and clinical studies. Several ...
The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations | Clinical Cancer...
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K ... S6). These results suggest that a selective class I PI3K inhibitor has an advantage over mTORC1 and PI3K/mTOR inhibitors in ... I PI3K inhibitor CH5132799 on the feedback loop compared with the mTORC1 inhibitor everolimus and the PI3K/mTOR dual inhibitor ... mTORC1 inhibitors abrogate this feedback suppression, resulting in Akt activation. On the other hand, PI3K inhibitors are ...
Celecoxib Decreases Ki-67 Proliferative Index in Active Smokers | Clinical Cancer Research
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung ... These mechanisms include abnormal expression of epithelial growth factors, epithelial and microvascular proliferation, ... This pilot study focused on the feasibility of using an oral COX-2 inhibitor, Celecoxib, as a chemopreventive agent to protect ... We hypothesized that treatment with oral Celecoxib, a selective COX-2 inhibitor, would favorably alter the biomarkers of lung ...
Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer | Clinical Cancer Research
In vivo studies in rodent models have shown orally administered everolimus to be a potent inhibitor of tumor growth at well- ... The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell ... Another mTOR inhibitor, temsirolimus (CCI-779) has been studied in SCLC. A randomized phase II trial in patients with extensive ... mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17:1717-34. ...
Epigenetic Modulation of Retinoic Acid Receptor β2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma |...
Several HDAC inhibitors have been characterized that inhibit tumor growth in vitro and in vivo and are in clinical trials (18 ... our results show that the tumor growth inhibition in severe combined immunodeficient mice is transient with the HDAC inhibitor ... Tumor growth in vivo. Male 4- to 6-week-old severe combined immunodeficient or athymic nude mice (NCI) were kept in a ... The HDAC inhibitor MS-275 was shown to increase H4 acetylation of the chromatin associated with RARβ2 promoter and to induce ...
Overexpression of the ATP-binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-resistant Human Breast...
Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib ... ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy ... a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing ... Senderowicz A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig. New Drugs, 17: ...
11C]Choline Positron Emission Tomography in Estrogen Receptor-Positive Breast Cancer | Clinical Cancer Research
Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997;15:2289-301. ... It is well recognized that although expression of markers such as ER, PR, HER-2, and epidermal growth factor receptor may alter ... In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 1999;59:3112- ... QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be? Curr Med Chem 2003;10:1095-112. ...
Transcription Factor Sp1 Expression Is a Significant Predictor of Survival in Human Gastric Cancer | Clinical Cancer Research
... epidermal growth factor receptor, insulin-like growth factor receptor 1 (28, 29, 30, 31) , insulin-like growth factor-binding ... Dennig J., Beato M., Suske G. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. EMBO J., 15: 5659- ... epidermal growth factor receptor, insulin-like growth factor receptor, interleukin 8, and vascular endothelial growth factor ( ... Insulinlike growth factor-binding protein modulates the growth response to insulinlike growth factor 1 by human gastric cancer ...
PT - JOURNAL ARTICLE
Experimental Design: TGFβ-mediated growth and Smad phosphorylation of MCF7, Hs578T, MDA-MB-231, and T47D human breast cancer ... Results: Human breast cancer cell lines pretreated with TGFβ small molecule inhibitor were radiosensitized, irrespective of ... a small molecule inhibitor of the TGFβ type I receptor kinase. The DNA damage response was assessed in irradiated MDA-MB-231 ... and promoted tumor growth delay, and thus may be an effective adjunct in cancer radiotherapy. Clin Cancer Res; 17(21); 6754-65 ...
Association of Increased Levels of Heavy-Chain Ferritin with Increased CD4+ CD25+ Regulatory T-Cell Levels in Patients with...
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of ... Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of ... Chen W., Jin W., Wahl S. M. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth ...
Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and...
Tumilasci VF, Oliere S, Nguyen TL, Shamy A, Bell J, Hiscott J. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes ... Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine ... Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to ... resulted in tumor growth delay, although the mechanism was not defined (35). The ability of VSV to purge LN metastases is also ...
Plus it
E, Tumor growth summary for all treatment groups (n = 14 per group). F, Individual tumor growth curves for all animals in the ... Only a subset of patients currently benefits from immune checkpoint inhibitors, thus highlighting an urgent need to improve ... 2D). Nanodisc vaccination alone efficiently slowed tumor growth (Fig. 2E) and eliminated tumors in 7 of 14 animals (Fig. 2F). ... All animals treated with soluble vaccine + anti-PD-L1 succumbed to tumor growth within 40 days without any statistical ...
Plus it
The seminal study in this area (5) showed that CTLA-4 blockade could attenuate the growth of several implanted murine tumors, ... The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide ... Combining ipilimumab with targeted therapy, such as the BRAF inhibitor vemurafenib, will almost certainly become an area of ...
Plus it
Palliative chemotherapy regimens have been improved by adding topoisomerase-I inhibitors and platin-based cytotoxic drugs. ... who is overwhelmed by an exponential growth of billions of destructive tumor cells. This has not worked with vaccines against ...